Armata Pharmaceuticals Inc (A:ARMP)

Business Focus: Biotechnology & Medical Research

Sector:  Healthcare Industry:  Biotechnology & Medical Research
 
See Regulatory Filings on SEC
Company Contact
Address: 5005 Mcconnell Ave
LOS ANGELES CA 90066
Tel: 1-212-9152569
Website: https://www.armatapharma.com
IR: See website
<
Key People
Deborah L. Birx
Chief Executive Officer, Director
Richard Rychlik
Principal Financial Officer
 
Business Overview
Armata Pharmaceuticals, Inc. is a clinical-stage biotechnology company focused on the development of pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using its bacteriophage-based technology. Th Company is engaged in developing and advancing a pipeline of natural and synthetic phage candidates, including clinical candidates for Pseudomonas aeruginosa, Staphylococcus aureus, and other pathogens. Its two lead candidates addresses both chronic and acute bacterial infections. The Company's first lead candidate focused primarily on chronic bacterial infections is the clinical phage candidate for Pseudomonas aeruginosa. In parallel, it has an acute bacterial infection clinical development plan focused on Staphylococcus aureus bacteremia, a difficult-to-treat and often life-threatening infection.
Financial Overview
For the fiscal year ended 31 December 2023, Armata Pharmaceuticals Inc revenues decreased 18% to $4.5M. Net loss increased 87% to $69M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Higher net loss reflects General & Adminstrative increase of 91% to $11.7M (expense), Interest expense increase from $0K to $2.6M (expense).
Employees: 66 as of Mar 1, 2024
Reporting Currency: U.S. Dollars
Enterprise value: $160.24M as of Dec 31, 2023
Annual revenue (TTM): $4.53M as of Dec 31, 2023
EBITDA (TTM): -$39.91M as of Dec 31, 2023
Net annual income (TTM): -$69.05M as of Dec 31, 2023
Free cash flow (TTM): -$55.57M as of Dec 31, 2023
Net Debt Last Fiscal Year: $68.78M as of Dec 31, 2023
Shares outstanding: 36,148,539 as of Mar 15, 2024
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.